Habib Jabagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Habib Jabagi has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Munir Boodhwani
University of Ottawa Heart Institute
6 shared publicationsGeorge Wells
Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Canada
5 shared publications- Louise Y. Sun
Stanford University School of Medicine
4 shared publications - Giuseppe Imperatore
Scuola Superiore Sant'Anna
2 shared publications Juan B. Grau
The Valley Hospital
2 shared publicationsPaul Burns
The Valley Hospital
2 shared publications
Latest Publications
- 16 November 2026
- Published by Wolters Kluwer Health in Anesthesiology
Perioperative Right Heart Failure in Cardiac Surgery: Reply
- 16 November 2026
- Published by Wolters Kluwer Health in Anesthesiology
Perioperative Right Heart Failure in Cardiac Surgery: Reply
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Exercise and Thoracic Aortic Aneurysms: A Paradigm Shift Toward Informed, Personalized Activity Guidelines
Exercise is widely recognized for its cardiovascular benefits; however, its safety and role in patients with thoracic aortic aneurysms (TAAs) remains complex due to its distinctive biomechanical vulnerabilities. Fundamentally different from abdominal aortic aneurysms, TAAs develop from distinct pathophysiological processes that affect their hemodynamic responses to stressors and influence their risk of adverse aortic events. Exercise induces acute hemodynamic changes, including increased stroke volume, systolic and pulse pressures, and transient aortic stiffening. These changes impose mechanical stress on the aortic wall, potentially accelerating aneurysm progression or triggering adverse aortic events. Although moderate aerobic exercise generally appears safe with potential cardiovascular benefits, evidence supporting safe practices in TAAs is limited. Current guidelines frequently extrapolate from abdominal aortic aneurysm data, which overlook the specificities of the thoracic aorta. This review underscores the urgent need for comprehensive research, using advanced imaging, biomarker profiling, and real‐time hemodynamic monitoring to understand how different exercise modalities and intensities affect TAAs. Well‐designed prospective studies are crucial to improve risk stratification, optimize antihypertensive strategies, develop personalized exercise prescriptions, and provide evidence‐informed guidance to patients. Perioperative strategies like prehabilitation and structured postoperative rehabilitation show promise but lack rigorous evaluation. Ultimately, this work advocates a paradigm shift from conservative inactivity toward informed, individualized physical activity regimens tailored to each patient's risk profile. This approach aims to maximize cardiovascular benefits while minimizing adverse aortic events, thereby improving overall health and quality of life in patients with TAAs.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Exercise and Thoracic Aortic Aneurysms: A Paradigm Shift Toward Informed, Personalized Activity Guidelines
Exercise is widely recognized for its cardiovascular benefits; however, its safety and role in patients with thoracic aortic aneurysms (TAAs) remains complex due to its distinctive biomechanical vulnerabilities. Fundamentally different from abdominal aortic aneurysms, TAAs develop from distinct pathophysiological processes that affect their hemodynamic responses to stressors and influence their risk of adverse aortic events. Exercise induces acute hemodynamic changes, including increased stroke volume, systolic and pulse pressures, and transient aortic stiffening. These changes impose mechanical stress on the aortic wall, potentially accelerating aneurysm progression or triggering adverse aortic events. Although moderate aerobic exercise generally appears safe with potential cardiovascular benefits, evidence supporting safe practices in TAAs is limited. Current guidelines frequently extrapolate from abdominal aortic aneurysm data, which overlook the specificities of the thoracic aorta. This review underscores the urgent need for comprehensive research, using advanced imaging, biomarker profiling, and real‐time hemodynamic monitoring to understand how different exercise modalities and intensities affect TAAs. Well‐designed prospective studies are crucial to improve risk stratification, optimize antihypertensive strategies, develop personalized exercise prescriptions, and provide evidence‐informed guidance to patients. Perioperative strategies like prehabilitation and structured postoperative rehabilitation show promise but lack rigorous evaluation. Ultimately, this work advocates a paradigm shift from conservative inactivity toward informed, individualized physical activity regimens tailored to each patient's risk profile. This approach aims to maximize cardiovascular benefits while minimizing adverse aortic events, thereby improving overall health and quality of life in patients with TAAs.
- 16 March 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-12
Patient-centered outcomes according to cancer status in cardiac surgery patients: a population-based cohort study
Background More cancer survivors are undergoing cardiac surgery, but their postoperative outcomes remain poorly understood. We aimed to describe the incidence and predictors of postoperative major adverse cardiovascular events (MACE) and patient-defined cardiovascular and non-cardiovascular events (PACE) by cancer status. Methods We conducted a retrospective cohort study (2016-2022) among U.S. adults (≥18 years) undergoing cardiac surgery in MarketScan and Medicare databases. Co-primary outcomes were MACE (stroke, heart failure, myocardial infarction, repeat revascularization) and PACE (stroke, heart failure, new-onset dialysis, long-term care admission, ventilator-dependence). Cox regression evaluated the association of cancer status with postoperative outcomes. Results Among 61,581 patients (74.1% male; mean age 61 ± 10.9 years), 5381 (8.7%) had cancer. Although cancer patients exhibited higher unadjusted MACE and PACE over 2.0 ± 1.7 years (p < 0.001), multivariable analyses showed no significant association between cancer status and MACE or PACE at 30-days or at long-term follow-up MACE (aHR 1.05, 95%CI [0.99–1.10]) and PACE (aHR 1.02, [0.96–1.08]). Blood (aHR 1.13, [1.01–1.26]) and lung cancers (aHR 1.32, [1.08–1.62]) were associated with increased MACE risk, while digestive (aHR 1.17, [1.00–1.36]) and blood (aHR 1.14, [1.01–1.28]) cancers were linked to higher PACE risk. Factors more strongly predictive of PACE than MACE included older age, female sex and valvular/complex surgeries. Discussion Cancer status alone should not preclude cardiac surgery. A personalised, multidisciplinary approach may help optimise outcomes and better manage risks in this high-risk population.
- 16 March 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-12
Patient-centered outcomes according to cancer status in cardiac surgery patients: a population-based cohort study
Background More cancer survivors are undergoing cardiac surgery, but their postoperative outcomes remain poorly understood. We aimed to describe the incidence and predictors of postoperative major adverse cardiovascular events (MACE) and patient-defined cardiovascular and non-cardiovascular events (PACE) by cancer status. Methods We conducted a retrospective cohort study (2016-2022) among U.S. adults (≥18 years) undergoing cardiac surgery in MarketScan and Medicare databases. Co-primary outcomes were MACE (stroke, heart failure, myocardial infarction, repeat revascularization) and PACE (stroke, heart failure, new-onset dialysis, long-term care admission, ventilator-dependence). Cox regression evaluated the association of cancer status with postoperative outcomes. Results Among 61,581 patients (74.1% male; mean age 61 ± 10.9 years), 5381 (8.7%) had cancer. Although cancer patients exhibited higher unadjusted MACE and PACE over 2.0 ± 1.7 years (p < 0.001), multivariable analyses showed no significant association between cancer status and MACE or PACE at 30-days or at long-term follow-up MACE (aHR 1.05, 95%CI [0.99–1.10]) and PACE (aHR 1.02, [0.96–1.08]). Blood (aHR 1.13, [1.01–1.26]) and lung cancers (aHR 1.32, [1.08–1.62]) were associated with increased MACE risk, while digestive (aHR 1.17, [1.00–1.36]) and blood (aHR 1.14, [1.01–1.28]) cancers were linked to higher PACE risk. Factors more strongly predictive of PACE than MACE included older age, female sex and valvular/complex surgeries. Discussion Cancer status alone should not preclude cardiac surgery. A personalised, multidisciplinary approach may help optimise outcomes and better manage risks in this high-risk population.
- Open Access
- 22 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 102069
Utilization of current ACC/AHA genetic testing recommendations for thoracic aortic disease at a large adult aortic center
- 22 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 102069
Open AccessUtilization of current ACC/AHA genetic testing recommendations for thoracic aortic disease at a large adult aortic center
- 1 May 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (5) , 1469-1475
Aortic Valve Repair Decreases Risks of VRE in AI at 10 Years: A Propensity Score–Matched Analysis
- 1 May 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (5) , 1469-1475
Aortic Valve Repair Decreases Risks of VRE in AI at 10 Years: A Propensity Score–Matched Analysis
- 21 March 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (6) , 1886-1896
Early and late outcomes of surgical aortic valve replacement with sutureless and rapid‐deployment valves versus transcatheter aortic valve implantation: Meta‐analysis with reconstructed time‐to‐event data of matched studies
Sutureless/rapid‐deployment (SURD) valves are options different from the stented prostheses included in the pivotal trials comparing surgical aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI). We performed a meta‐analysis with reconstructed time‐to‐event data of matched studies published by November 2021 to compare SURD‐AVR and TAVI. Primary endpoints were 30‐day mortality and overall survival in the follow‐up. Secondary endpoints included: 30‐day stroke, acute kidney injury (AKI), major bleeding, permanent pacemaker implantation (PPI), paravalvular leak (PVL), prosthesis‐patient mismatch (PPM), postoperative aortic valve area (AVA), and mean gradients. Ten studies met our eligibility criteria, including a total of 5134 patients (2567 underwent SURD‐AVR and 2567 underwent TAVI). Pooled risk of 30‐day mortality did not favor any group (odds ratio [OR]: 0.69; 95% confidence interval [CI]: 0.31–1.53; p = 0.360). Patients undergoing SURD‐AVR had lower risk of PVL (OR: 0.09; 95% CI: 0.05–0.17; p < 0.001). No statistically significant differences were observed for 30‐day stroke, AKI, major bleeding, PPI, PPM, and postoperative AVA. In the follow‐up, we observed a higher risk of mortality (hazard ratio: 1.74; 95% CI: 1.26–2.40; p < 0.001) with TAVI. Patients who underwent SURD‐AVR experienced better survival, however, the interpretation of these results warrant caution due to the fact that SURD‐AVR patients tended to be younger than TAVI patients. Structural heart surgeons and interventional cardiologists should consider initial risk and life expectancy when referring patients for one approach over the other.
- 21 March 2022
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (6) , 1886-1896
Early and late outcomes of surgical aortic valve replacement with sutureless and rapid‐deployment valves versus transcatheter aortic valve implantation: Meta‐analysis with reconstructed time‐to‐event data of matched studies
Sutureless/rapid‐deployment (SURD) valves are options different from the stented prostheses included in the pivotal trials comparing surgical aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI). We performed a meta‐analysis with reconstructed time‐to‐event data of matched studies published by November 2021 to compare SURD‐AVR and TAVI. Primary endpoints were 30‐day mortality and overall survival in the follow‐up. Secondary endpoints included: 30‐day stroke, acute kidney injury (AKI), major bleeding, permanent pacemaker implantation (PPI), paravalvular leak (PVL), prosthesis‐patient mismatch (PPM), postoperative aortic valve area (AVA), and mean gradients. Ten studies met our eligibility criteria, including a total of 5134 patients (2567 underwent SURD‐AVR and 2567 underwent TAVI). Pooled risk of 30‐day mortality did not favor any group (odds ratio [OR]: 0.69; 95% confidence interval [CI]: 0.31–1.53; p = 0.360). Patients undergoing SURD‐AVR had lower risk of PVL (OR: 0.09; 95% CI: 0.05–0.17; p < 0.001). No statistically significant differences were observed for 30‐day stroke, AKI, major bleeding, PPI, PPM, and postoperative AVA. In the follow‐up, we observed a higher risk of mortality (hazard ratio: 1.74; 95% CI: 1.26–2.40; p < 0.001) with TAVI. Patients who underwent SURD‐AVR experienced better survival, however, the interpretation of these results warrant caution due to the fact that SURD‐AVR patients tended to be younger than TAVI patients. Structural heart surgeons and interventional cardiologists should consider initial risk and life expectancy when referring patients for one approach over the other.
- 27 August 2020
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 12 (5) , 656-658
Pulmonary Autograft Coronary-Cameral Fistula Leading to LVOT Pseudoaneurysm Post Ross Procedure
We report the case of a presumed coronary-cameral fistula arising directly below the commissures of the noncoronary cusp (NCC) and left coronary cusp (LCC) of the pulmonary autograft, leading to left ventricular outflow tract pseudoaneurysm and late tamponade post Ross procedure.
- 27 August 2020
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 12 (5) , 656-658
Pulmonary Autograft Coronary-Cameral Fistula Leading to LVOT Pseudoaneurysm Post Ross Procedure
We report the case of a presumed coronary-cameral fistula arising directly below the commissures of the noncoronary cusp (NCC) and left coronary cusp (LCC) of the pulmonary autograft, leading to left ventricular outflow tract pseudoaneurysm and late tamponade post Ross procedure.
- Open Access
- 9 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-13
COMMENCE trial (Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry): a randomized controlled trial of mild vs moderate hypothermia on patient outcomes in aortic hemiarch surgery with anterograde cerebral perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated, supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-center RCT in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI).Methods/design: This is a prospective multi-center, single-blind two-arm RCT comparing mild (32 °C) versus moderate (26 °C) hypothermic cardiac arrest in patients (n = 282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures.Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon’s discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling center standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60 ± 14 days.Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32 °C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the health care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.Trial registration: This trial is registered on ClinicalTrials.gov with the registration numberNCT02860364. Registration date August 9th, 2016.
- 9 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-13
Open AccessCOMMENCE trial (Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry): a randomized controlled trial of mild vs moderate hypothermia on patient outcomes in aortic hemiarch surgery with anterograde cerebral perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated, supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-center RCT in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI).Methods/design: This is a prospective multi-center, single-blind two-arm RCT comparing mild (32 °C) versus moderate (26 °C) hypothermic cardiac arrest in patients (n = 282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures.Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon’s discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling center standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60 ± 14 days.Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32 °C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the health care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.Trial registration: This trial is registered on ClinicalTrials.gov with the registration numberNCT02860364. Registration date August 9th, 2016.
- Open Access
- 1 October 2019
- Published by Springer Nature in Research Square
COMMENCE Trial – Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry A Randomized Controlled Trial of Mild vs Moderate Hypothermia on Patient Outcomes in Aortic Hemiarch Surgery with Anterograde Cerebral Perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-centre RCT, in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI). Methods: This is a prospective multi-centre, single-blind two-arm RCT comparing mild (32°C) versus moderate (26°C) hypothermic cardiac arrest in patients (n=282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures. Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon's discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling centre standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60±14 days. Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32°C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the Health Care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.
- 1 October 2019
- Published by Springer Nature in Research Square
Open AccessCOMMENCE Trial – Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry A Randomized Controlled Trial of Mild vs Moderate Hypothermia on Patient Outcomes in Aortic Hemiarch Surgery with Anterograde Cerebral Perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-centre RCT, in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI). Methods: This is a prospective multi-centre, single-blind two-arm RCT comparing mild (32°C) versus moderate (26°C) hypothermic cardiac arrest in patients (n=282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures. Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon's discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling centre standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60±14 days. Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32°C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the Health Care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.
- Open Access
- 1 October 2019
- Published by Springer Nature in Research Square
COMMENCE Trial – Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry A Randomized Controlled Trial of Mild vs Moderate Hypothermia on Patient Outcomes in Aortic Hemiarch Surgery with Anterograde Cerebral Perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-centre RCT, in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI). Methods: This is a prospective multi-centre, single-blind two-arm RCT comparing mild (32°C) versus moderate (26°C) hypothermic cardiac arrest in patients (n=282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures. Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon's discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling centre standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60±14 days. Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32°C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the Health Care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.
- 1 October 2019
- Published by Springer Nature in Research Square
Open AccessCOMMENCE Trial – Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry A Randomized Controlled Trial of Mild vs Moderate Hypothermia on Patient Outcomes in Aortic Hemiarch Surgery with Anterograde Cerebral Perfusion
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-centre RCT, in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI). Methods: This is a prospective multi-centre, single-blind two-arm RCT comparing mild (32°C) versus moderate (26°C) hypothermic cardiac arrest in patients (n=282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures. Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon's discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling centre standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60±14 days. Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32°C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the Health Care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.